RE: PRIMARY CARE AND UROLOGY PATIENTS WITH THE MALE PELVIC PAIN SYNDROME: SYMPTOMS AND QUALITY OF LIFE

2002 ◽  
Vol 168 (5) ◽  
pp. 2134-2135
Author(s):  
Christopher E. Ramsden ◽  
Michael McDaniel
2002 ◽  
pp. 1768-1773 ◽  
Author(s):  
JUDITH A. TURNER ◽  
STEPHANIE HAUGE ◽  
MICHAEL VON KORFF ◽  
KATHLEEN SAUNDERS ◽  
MARC LOWE ◽  
...  

2002 ◽  
Vol 167 (4) ◽  
pp. 1768-1773 ◽  
Author(s):  
Judith A. Turner ◽  
Stephanie Hauge ◽  
Michael Von Korff ◽  
Kathleen Saunders ◽  
Marc Lowe ◽  
...  

2007 ◽  
Vol 177 (4S) ◽  
pp. 31-31
Author(s):  
J. Curtis Nickel ◽  
Dean Tripp ◽  
Shannon Chuai ◽  
Mark S. Litwin ◽  
Mary McNaughton-Collins

2018 ◽  
Vol 10 (12) ◽  
pp. 377-381 ◽  
Author(s):  
Andrea Benelli ◽  
Simone Mariani ◽  
Virginia Varca ◽  
Andrea Gregori ◽  
Franco Barrese ◽  
...  

Background: Chronic prostatitis/chronic pelvic pain syndrome (IIIB CP/CPPS) is a condition of unclear aetiology. Many approaches have been used without satisfactory results. The aim of this study is to evaluate the efficacy of once-daily 5 mg tadalafil in pain control and improving quality of life in patients affected by CP/CPPS. Methods: Twenty patients affected by chronic prostatitis according EAU (European Association of Urology) guidelines were evaluated for once-daily 5 mg tadalafil; 14 patients were eligible for the study. The validated Italian version of the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) and the International Prostatic Symptom Score (IPSS) questionnaires were submitted to all the patients. Every patient underwent uroflowmetry and ultrasound prostatic volume at the beginning and at the end of the study. Results: All 14 patients eligible for the study reported an improvement of symptoms during therapy: statistically significant differences were reported in terms of NIH-CPSI ( p < 0.000002) and IPSS ( p < 0.0001) during follow-up evaluations. No statistically significant improvement of uroflowmetry parameters was reported during the treatment. Conclusions: In our study the daily use of 5 mg tadalafil improves symptoms and quality of life in patients affected by CP/CPPS after 4 weeks of therapy. A larger population of patients is needed to confirm the efficacy of this therapy in CP/CPPS.


2020 ◽  
Vol 73 (12) ◽  
pp. 2623-2626
Author(s):  
Nikolay A. Shcherbina ◽  
Liliya V Potapova ◽  
Irina N. Shcherbina ◽  
Oksana P. Lipko ◽  
Olga V. Mertsalova ◽  
...  

The aim: About 10% of socially active women of reproductive age suffer from endometriosis, is determined by the frequent occurrence of menstrual and reproductive functions disorders, and pelvic pain syndrome in patients. The difficulties of therapeutic treatment of chronic pain syndrome in external genital endometriosis (EGE) are associated with polymorphism of pain mechanisms, and delayed diagnosis and treatment. The aim of the study is to improve the effectiveness of the treatment of external genital endometriosis. Material and methods: We examined 60 female patients of reproductive age, 40 – with histologically verified diagnosis of external genital endometriosis and 20 healthy women. We used the following methods of examination: general clinical, instrumental, endoscopic, morphological, the Visual Analogue Scale (VAS) to quantify pain, the Beck Depression Scale and the SF-36 questionnaire. Results: Before the treatment of patients with EGE, VAS scale scores indicated pain in 100% of patients, the indicators of depression and level of anxiety go beyond the normative. The results of the pre-treatment questionnaire indicated lower quality of life scores on the scales of physical and mental health components. As a result of treatment there was significant decrease in the manifestations of pain, depression and anxiety, with women receiving complex therapy (hormone therapy got antidepressants and non-drug correction methods). Сonclusions: Chronic pelvic pain syndrome associated with EGE and accompanied by an unfavorable psychological state, depressive states, anxiety symptoms, and psychosomatic disorders. New approaches to the treatment of clinical manifestations of EGE are needed, taking into account patients’ psycho-emotional status and the life quality analysis. We pathogenetically justified the use of drugs that affect the psychosomatic status of patients with EGE and showed that they could significantly improve the quality of life.


2017 ◽  
Vol 2017 ◽  
pp. 1-15 ◽  
Author(s):  
Maria Beatrice Passavanti ◽  
Vincenzo Pota ◽  
Pasquale Sansone ◽  
Caterina Aurilio ◽  
Lorenzo De Nardis ◽  
...  

Chronic Pelvic Pain (CPP) and Chronic Pelvic Pain Syndrome (CPPS) have a significant impact on men and women of reproductive and nonreproductive age, with a considerable burden on overall quality of life (QoL) and on psychological, functional, and behavioural status. Moreover, diagnostic and therapeutic difficulties are remarkable features in many patients. Therefore evaluation, assessment and objectivation tools are often necessary to properly address each patient and consequently his/her clinical needs. Here we review the different tools for pain assessment, evaluation, and objectivation; specific features regarding CPP/CPPS will be highlighted. Also, recent findings disclosed with neuroimaging investigations will be reviewed as they provide new insights into CPP/CPPS pathophysiology and may serve as a tool for CPP assessment and objectivation.


2009 ◽  
Vol 56 (1) ◽  
pp. 81-89 ◽  
Author(s):  
B.R. Cvetkovic ◽  
Z.P. Cvetkovic ◽  
D. Milenkovic ◽  
A. Adamovic

Introduction: Chronic pelvic pain syndrome (CPPS) is defined as pelvis minor pain of nonmalignant nature repeating in different time intervals. Urethral syndrome (US) represents a most poorly defined entity within CPPS. Objective: The estimation of US influence on quality of-life as well as the determination of the way of treatment and therapy optimal length. Material and methods: A prospective one-year study included 166 men with CPPS, median age of 54 years; they were monitored clinically. During the patient monitoring the NIH-CPSI questionnaire (National Institute of Health- Chronic Prostatis Symptom Index) was used. US was diagnosed in 79 patients (47%), and according to the most intensive pain localization they were divided into three groups. All the patients were treated with alpha adrenergic blockers and non-steroidal anti-inflammatory drugs, and the treatment of the patients with positive urethral smear also included antibiotherapy. The values of total NIHCPSI, as well as of its individual components were analyzed after three and six months of treatment. Results and discussion: The therapy application had a significant influence on the decrease of total NIH-CPSI - 23.3% (p<0,01), pain symptoms (p<0.0) and urinary difficulties (p<0.01), and the point values of quality-of-life score were diminished by 0.7 to 1.9 points depending on the group of those monitored (p<0.01). Conclusion: Our study indicated a significant influence of CPPS on quality-of-life and a necessity of a serious approach to patients and their treatment.


Sign in / Sign up

Export Citation Format

Share Document